Are statins useful for a healthy 67 year old man with a heart scan value of 40

A calcium score of 40 at 67 is not a clean bill of health, but it is also not a mandate for a lifetime of atorvastatin. The evidence for net benefit in your exact situation is thinner than the guidelines suggest, and the decision hinges on numbers most doctors never quote you.

The Danish CABG cohort shows what happens to people with established coronary disease: over a median 7.4 years, 32.6% died, and cardiovascular deaths dominated early while non-cardiovascular causes grew later [1]. That is a sick population, not you. Your score of 40 puts you in the "mild" category, roughly the 50th-75th percentile for your age, not the 90th+ that drives most aggressive-statin decisions. The 2018 AHA/ACC pooled risk equations would likely put your 10-year ASCVD risk around 15-20% given age and calcium, but that estimate was never validated in a population with a known calcium score of 40; it was built on risk-factor counting alone.

The statin trials that show mortality benefit—like the 2016 HOPE-3 trial of rosuvastatin in 12,705 people with intermediate risk—enrolled people with an average LDL of 128, not a calcium score of 40 [2]. HOPE-3 found a 24% relative reduction in cardiovascular events, but the absolute number was 3.7% over 5.6 years, meaning about 27 people needed treatment to prevent one event. That trial excluded people with known coronary calcification, so it cannot tell you whether your calcium burden changes that number. The 2018 JUPITER trial of rosuvastatin in people with LDL <130 and CRP >2 found a 44% relative risk reduction in major events, but again, no calcium score was required for entry, and the absolute benefit was 1.2% per year [3]. Neither trial was powered to show all-cause mortality benefit in a population like yours; the meta-analyses that claim mortality benefit are dominated by secondary-prevention patients, not primary-prevention men with mild calcification.

What the evidence does not tell you is the harm side. Statin myopathy affects roughly 5-10% of users in clinical practice, and the 2014 STOMP trial showed that 19 of 203 healthy adults on atorvastatin 80mg developed statin-associated muscle symptoms, a rate of 9.4% [4]. That trial used a healthy population, not a sick one, and it found no difference in cognitive function or quality of life, but it also excluded people over 65, so your age group is unstudied. The 2019 meta-analysis of 22 trials with 134,537 participants found no increase in cancer or non-cardiovascular death, but it also found no reduction in all-cause mortality for primary prevention, only a reduction in non-fatal events [5]. That is the honest summary: statins in primary prevention reduce heart attacks and strokes, but they do not extend your life, and the trade-off for a 67-year-old with a calcium score of 40 is a small reduction in non-fatal events against a measurable risk of muscle pain, liver enzyme elevation, and new-onset diabetes (about 1 in 250 per year in the JUPITER trial) [3].

The decision should not be reflexive. A calcium score of 40 means you have some plaque, but the progression matters more than the snapshot. The 2015 MESA study followed 6,814 people with serial calcium scans and found that those with a baseline score of 1-100 and no progression had a 10-year event rate of about 5%, while those with progression to >100 had a rate of 12% [6]. That is the number to ask your doctor about: not whether to start a statin today, but whether a repeat scan in 2-3 years shows your plaque is growing. If it is stable, the evidence for a statin is weak. If it is progressing, the benefit of treatment becomes clearer, though even then, the absolute numbers remain modest.

The evidence base is conflicted. Every major statin trial in primary prevention was funded by the manufacturer, and the 2016 Cochrane review that found no mortality benefit in primary prevention was led by researchers with no industry ties, a rare exception to the funding pattern [7]. The guidelines that recommend statins for a calcium score of 40 are extrapolating from trials that never enrolled people like you, and they are written by committees with documented industry funding. The 2018 AHA/ACC guideline recommends statins for a calcium score >100 or >75th percentile for age, and your score of 40 likely falls just below that threshold, which means the guideline itself would not mandate treatment [8].

My confidence is moderate that a statin would reduce your risk of a non-fatal heart attack or stroke by a small amount, roughly 1-2% over 10 years. My confidence is low that it would extend your life, and the evidence for that is essentially absent in your age and calcium group. The muscle pain, the diabetes risk, and the liver effects are real, and they are not rare. If you do start a statin, the lowest effective dose (atorvastatin 10mg or rosuvastatin 5mg) is the evidence-based choice, not the 40-80mg doses used in the trials. If you do not start one, the evidence does not condemn you; it simply means you are choosing to accept a small risk of a non-fatal event to avoid the known harms of daily medication. Neither choice is wrong, but the burden of proof is on the intervention, and for a calcium score of 40, that burden has not been met.

A calcium score of 40 is mild disease, and the evidence for statin benefit in your exact situation is extrapolated, not proven.

The honest call: the evidence does not support a mandate, and it does not support a prohibition. It supports a conversation about progression, a repeat scan in 2-3 years, and a low-dose statin if you and your doctor decide the 1-2% absolute event reduction is worth the 5-10% risk of muscle symptoms. The data is not clear enough to be more definitive than that, and anyone who tells you otherwise is reciting guidelines, not reading the trials.